Over the next five years, the expiration of several high-value drug patents will open new opportunities for biosimilar and generic manufacturers. This ongoing trend will enable these companies to expand their market presence, enhance competition, and offer more affordable treatment options to patients worldwide.

Nearly 110 biologic products** are expected to lose exclusivity (LoE) in Europe by the end of 2032, although many of these products currently have no biosimilar candidates in development. Companies that act swiftly with robust development, regulatory, and commercialization strategies will be well-positioned to capitalize on this wave of patent expirations and strengthen
their global presence.